Comparison of efficacy and adverse events in patients on ibandronate therapy delivered orally (50 mg) or intravenously (6 mg)
| Patients reporting/total no | ||
|---|---|---|
| Oral 50 mg | Intravenous 6 mg | |
| Efficacy | ||
| SREs | 430/1018 (42%) | 119/266 (45%) |
| Adverse event | ||
| Abdominal pain | 192/1013 (19%) | 7/112 (6%) |
| Anorexia | 254/704 (36%) | 28/65 (43%) |
| Diarrhoea | 210/726 (30%) | 7/112 (6%) |
| Fatigue | 551/704 (78%) | 30/65 (46%) |
| Fever or influenza-like symptoms | 279/704 (36%) | 10/154 (14%) |
| Nausea | 428/1013 (42%) | 32/65 (49%) |
| Renal toxicity | 245/1018 (24%) | 5/154 (3%) |
SREs, skeletal-related events.